Drug-coated Balloons in the Neurovascular Setting: A Comprehensive, Systematic Review of Current Use and Indications

^*Correspondence: p.vongottberg@klinikum-stuttgart.de (Philipp von Gottberg)
Academic Editors: Massimo Volpe, Filippos Triposkiadis, Grigorios Korosoglou and Matteo Cameli

Rev. Cardiovasc. Med. 2022, 23(4), 128; https://doi.org/10.31083/j.rcm2304128

Submitted: 10 December 2021 | Revised: 13 January 2022 | Accepted: 21 January 2022 | Published: 2 April 2022

(This article belongs to the Special Issue State-of-the-Art Cardiovascular Medicine in Europe 2022)

This is an open access article under the CC BY 4.0 license.

View Full-text

Download PDF

Cite

Abstract

Background: Drug-coated balloons (DCB) are an established tool in the prevention and treatment of coronary and peripheral artery restenosis. The underlying effects of restenosis resemble those in the neurovascular field, yet data on the use of DCB in cervical and intracranial arteries is rare. Methods: Medline, and international and major national guidelines and recommendations were systematically searched for data addressing the use of DCB in the neurovascular setting. Results: Of the 1448 relevant records found in Medline, 166 publications were considered for this review. Conclusions: Data on the use of DCB in the neurovascular setting show a possible benefit over preceding alternatives, such as self-expanding stents, and balloon-mounted or drug-eluting stents. Nonetheless, the role of DCB remains under-researched, and publications remain lacking.

Keywords

drug-coated balloons

percutaneous transluminal angioplasty

neurovascular

neurointerventional

arterial stenosis

carotid artery stenosis

intracranial atherosclerotic stenosis

stroke

paclitaxel

Previous article in this issue

Next article in this issue

Rev. Cardiovasc. Med. Print ISSN 1530-6550 Electronic ISSN 2153-8174